AKTX Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
Cost of Revenue
0
0
0
0
0
Gross Profit
Operating Expenses
15.8M
+388.3%
3.2M
-56.4%
7.4M
+137.4%
3.1M
-11.5%
3.5M
R&D
1.5M
+34.3%
1.1M
+336.1%
249.0K
-62.7%
667.0K
-18.0%
813.0K
SG&A
2.2M
+1.3%
2.1M
+8.4%
2.0M
-19.5%
2.5M
-9.6%
2.7M
Operating Income
-15758000
-388.3%
-3227000
+56.4%
-7404000
-137.4%
-3119000
+11.5%
-3525000
EBITDA
-3628000
-12.4%
-3227000
-45.1%
-2224000
+28.7%
-3119000
+11.5%
-3525000
Net Income
-14455000
-172.8%
-5298000
+17.2%
-6400000
-237.7%
-1895000
+48.9%
-3705000
EPS (Basic)
EPS (Diluted)
Shares (Diluted)
118.8B
+6955.4%
1.7B
+3.1%
1.6B
+3.8%
1.6B
-97.1%
54.6B
Akari Therapeutics plc (0.01 USD) (AKTX) — Financials